PubMed COVID-19 Clinical Care

CONCLUSIONS: Strong immune responses following first COVID-19 infection and subsequent vaccination with the BNT162b2 vaccine provided cross-protection against reinfections with Delta and Omicron variants.

CONCLUSION: Following confinement, cognition continued to decline, but NPS demonstrated either stability or improvement. This highlights the role modifiable risk factors may have on the progression of NPS.

Surfaces contaminated with infectious SARS-CoV-2 particles have the potential to cause human infection and any increase in surface survivability of a SARS-CoV-2 variant may increase its prevalence over other variants. This study investigated whether

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in more than 670 million infections and almost 7 million deaths globally. The emergence of numerous SARS-CoV-2 has heightened

Numerous state, national, and global resources exist for planning and executing mass vaccination campaigns. However, they are disparate and can be complex. The COVID-19 pandemic highlighted the need for clear, easy to use mass vaccination resources

No abstract

No abstract

CONCLUSION: SOF/DCV may reduce mortality rate and need for ICU/IMV in patients with COVID-19 while increasing the chance for clinical recovery.

No abstract

A 44-year-old female patient with multiple sclerosis (MS) treated with ocrelizumab was hospitalized with SARS-CoV-2 pneumonia three times over the course of five months, eventually expiring. Viral sequencing of samples from her first and last